

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

VOLUNTARY ANNOUNCEMENT

BUSINESS COOPERATION WITH BSC INTERNATIONAL MEDICAL TRADING (SHANGHAI) CO., LTD.

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that on July 1, 2024, the Group entered into a distribution agreement (the “**Distribution Agreement**”) with BSC International Medical Trading (Shanghai) Co., Ltd. in respect of respiratory intervention products in mainland China. BSC International Medical Trading (Shanghai) Co., Ltd. is a subsidiary of Boston Scientific Corporation (a company listed on the New York Stock Exchange (stock symbol: BSX)) in China. Boston Scientific is a global leader in medical technology, advancing life sciences by providing a broad range of high-performance solutions that address patient needs and reduce the cost of healthcare. Boston Scientific’s portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Pursuant to the Distribution Agreement, the Group and BSC International Medical Trading (Shanghai) Co., Ltd. confirmed their strategic collaboration in respect of respiratory intervention products in mainland China. The Group will market, promote and serve as the exclusive distributor of BSC International Medical Trading (Shanghai) Co., Ltd. for products in the respiratory intervention field in mainland China, combining the resources and support of BSC International Medical Trading (Shanghai) Co., Ltd. and the Group to promote the commercialization of such designated products in mainland China.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) believes that the Distribution Agreement provides a valuable opportunity for the parties to establish a strategic cooperation arrangement, lays a solid foundation for creating synergies in the respiratory intervention field and advances the integration of market resources and deployment for the launch of the Group’s subsequent respiratory intervention products by leveraging on the parties’ respective business layouts, expertise and resources in the respiratory intervention field. Therefore, the Board is of the view that the entering into of the Distribution Agreement is in the interests of the Company and its shareholders as a whole.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, each of BSC International Medical Trading (Shanghai) Co., Ltd. and its ultimate beneficial owners is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, July 1, 2024

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.